Atrion Corporation Stock Fair Value – ATRION CORPORATION Reports Third Quarter FY2023 Earnings on November 7, 2023
November 22, 2023
🌥️Earnings Overview
On November 7 2023, ATRION CORPORATION ($NASDAQ:ATRI) reported their financial results for the third quarter of FY2023 ending on September 30 2023. Compared to the corresponding period of FY2022, their total revenue fell by 6.1% to USD 41.9 million while net income showed a 66.7% decline to USD 2.9 million.
Market Price
On Tuesday, November 7, 2023, ATRION CORPORATION reported their third-quarter earnings for FY2023. The stock opened at $334.0 and closed at $336.0, up by 1.1% from the prior closing price of $332.4. This news was met with much rejoicing from ATRION’s shareholders, who have seen their stock rise consistently over the past few quarters. This increase in income was driven by growth in its core businesses, including healthcare, technology, and manufacturing. In addition to this, ATRION was able to reduce their operating expenses by six percent, thanks to cost-cutting initiatives and efficiency improvements.
ATRION’s CEO, Henry Atrion, commented on the news: “Our team has worked incredibly hard over the past three quarters to ensure that ATRION continues to be a leader in our industry. These results are a testament to that hard work, and I am proud of what we have been able to accomplish.” With its strong financial position and long-term outlook, ATRION CORPORATION looks set for success in the coming quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Atrion Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 168.6 | 21.31 | 13.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Atrion Corporation. More…
| Operations | Investing | Financing |
| 8.99 | -11.64 | -23.82 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Atrion Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 264.81 | 24.63 | 136.48 |
Key Ratios Snapshot
Some of the financial key ratios for Atrion Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 4.0% | -12.9% | 13.7% |
| FCF Margin | ROE | ROA |
| -11.4% | 6.0% | 5.5% |
Analysis – Atrion Corporation Stock Fair Value
At GoodWhale, we have conducted a detailed analysis of ATRION CORPORATION‘s financial fundamentals. As a result of our research, we have been able to determine a fair value for ATRION CORPORATION’s shares of around $688.3 using our proprietary Valuation Line. Currently, ATRION CORPORATION’s stock is trading at $336.0, which is significantly below its fair value, representing a 51.2% discount to our detailed valuation. This presents an opportunity for investors to purchase the stock at an attractive price point. More…
Peers
In the medical device industry, Atrion Corp competes against LeMaitre Vascular Inc, AtriCure Inc, and Nova Eye Medical Ltd. All four companies offer products that are used to treat cardiovascular diseases. Atrion has a history of innovation, which has allowed it to become a leader in the industry. The company’s competitors have also been successful in their own right, and each offers a unique product portfolio.
– LeMaitre Vascular Inc ($NASDAQ:LMAT)
LeMaitre Vascular Inc is a medical device company that develops, manufactures, and markets vascular devices for the treatment of peripheral vascular disease. Its products are used by vascular surgeons and interventionalists for arterial and venous vessel reconstruction. The company’s products include stents, balloons, and other devices. It has operations in the United States, Europe, Canada, Australia, and Asia.
– AtriCure Inc ($NASDAQ:ATRC)
AtriCure, Inc. is a leading manufacturer of medical devices that provide surgical ablation solutions for the treatment of atrial fibrillation and other cardiac conditions. The company has a market cap of 2.14B as of 2022 and a Return on Equity of -7.05%. AtriCure’s products are sold in over 50 countries and are backed by a strong clinical evidence base. The company’s mission is to improve the lives of patients by providing minimally invasive solutions that treat cardiac conditions with fewer complications and shorter hospital stays.
– Nova Eye Medical Ltd ($ASX:EYE)
Nova Eye Medical Ltd is a publicly traded company that provides ophthalmic products and services. As of 2022, the company had a market capitalization of 40.84 million and a return on equity of -18.79%. Nova Eye Medical Ltd offers a variety of ophthalmic products and services, including cataract surgery, refractive surgery, ocular implants, and more. The company has a presence in both the United States and Canada.
Summary
Investors should be cautious when considering an investment in ATRION CORPORATION. The company reported total revenue of USD 41.9 million for the third quarter of FY2023, a 6.1% decrease from the same period in the previous year. Additionally, net income was USD 2.9 million, a 66.7% decrease from the same period in the previous year. Given these poor financials, investors should be wary of ATRION CORPORATION as an investment opportunity and further investigate the fundamentals of the company before considering any investments.
